TMEFF2 and neoplasm: The results showed that patients whose primary tumours showed low TMEFF2 methylation achieved longer survival and a better prognosis than patients whose primary tumours exhibited high TMEFF2 methylation (HR = 0.35, P < 0.001; Fig. 5a).